Table 2.

Summary of the Current Case and 3 Reported Cases of Sarcoidosis-like-reaction after COVID-19 Vaccination.

Case	Type of Vaccine	Age	Sex	Race	Onset	Clinical manifestations	Laboratory findings	Radiographical findings	Histopathological findings	Treatment and outcome	Reference
1	1st & 2nd: BNT162b2 (Pfizer/BioNTech)	44	M	N.D.	A few days after 1st injection	Not reported	N.D.	CT, FDG-PET: axillary and mediastinal lymphadenopathy	EBUS-TBNA: sarcoidal-type granulomatous inflammation	N.D.	(17)
2	1st: ChAdOx1 (AstraZeneca) 2nd: CX-024414 (Morena)	21	F	Caucasian	3 weeks after 2nd injection	Löfgren’s syndrome ・skin rash ・ankle joint pain	CRP: 0.028 mg/dL, ACE: normal	CXR: not remarkable	N.D.	Ibuprofen: not effective, PSL 20 mg/day: effective	(18)
3	1st: ChAdOx1 2nd: N.D.	28	M	Caucasian	28 days after 1st injection	Löfgren's syndrome ・skin rash ・ankle joint pain ・BHL	CRP: 0.022 mg/dL, ESR: 80 mm/h, sIL-2R: 854 U/L, D-dimer: elevated, ACE: normal	CXR & CT: BHL and fine nodular shadow in lung parenchyma, PAE	N.D.	PSL 20 mg/day: effective, anticoagulant: effective	(18)
4	1st & 2nd: BNT162b2	61	M	Japanese	One day after 1st injection	Low grade fever malaise uveitis	CRP: 0.08 mg/mL, sIL-2R: 1,455 U/L, ACE: 25.8 U/L	CXR & CT: BHL, Ga-67 scintigraphy: increased uptake in ocular lesion and bilateral hilar and mediastinal lymph nodes	TBLB, EBUS-TBNA: non-caseating granuloma with giant cells	Topical steroid: effective	Current case

M: male, F: female, CT: computed tomography, CXR: chest X ray, FDG-PET: [¹⁸F] fluorodeoxyglucose-positron emission tomography, CRP: c-reactive protein, ESR: erythrocyte sediment rate, sIL2-R: soluble interleukin 2 receptor, ACE: angiotensin converting enzyme, BHL: bilateral hilar lymphadenopathy, PAE: pulmonary artery embolism, TBLB: trans-bronchial lung biopsy, Ga-67 scintigraphy:gallium-67 scintigraphy, EBUS-TBNA: endobronchial ultrasound-guided trans-bronchial needle aspiration, PSL: predonisolone, N.D.: not detailed